Beleave Inc. (CSE:BE) (“Beleave” or the “Company”) is pleased to announce that its wholly owned subsidiary Beleave Kannabis Corp. has received its approval and provider number to service those who have qualified for cannabis coverage through Medavie Blue Cross including the Canadian veteran community.  With over 1,000,000 card holders Medavie Blue Cross is one of Canada’s leading Blue Cross plans and although each card holder’s benefits may differ, cannabis coverage is available to patients approved by Blue Cross.

Medavie Blue Cross administers to various government sponsored health programs on behalf of the provincial and federal governments which include Veterans Affairs Canada, an important segment of Beleave’s patient acquisition strategy.


“We aim to help provide ease of access to those with Blue Cross coverage allowing patients to cut a multitude of steps typically needed to make a claim,” commented Beleave CEO Andrew Wnek. “Our team is ready to accept new patients and are confident in our ability to provide the highest quality service to all patients including our country’s respected servicemen and women.”

The Company’s Medi Green Clinic network plans to host multiple location information sessions for veterans on an ongoing basis.  These initiatives will be rolled out by the Company’s growing Veteran Affairs and Community outreach division.  To stay informed please join the company mailing list at www.beleave.com.

About Medavie Blue Cross
Medavie is a non-profit Canadian Medical care insurance company headquartered in Moncton, New Brunswick.  The Company was named one of Canada’s Top 100 Employers by Maclean’s magazine and is the only non-profit medical insurance organization in Canada to receive this honour.

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

Click here to connect with Beleave Inc. (CSE:BE) for an Investor Presentation.

Source: www.newswire.ca

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less